Ionizable Cationic Lipid for Gene Therapy Delivery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current lipid nanoparticles (LNPs) used for gene therapy face challenges in achieving efficient in-vivo delivery and cytotoxicity due to the selection of cationic lipids, which affect the entrapment efficiency and stability of nucleic acid drugs.
Innovation Solution
Development of a novel cationic lipid compound with a specific structure that can form a lipid carrier, allowing for controlled, uniform distribution and high entrapment efficiency of nucleic acid drugs, and exhibiting pH-responsive electric properties to minimize cytotoxicity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional cationic lipids are used in lipid nanoparticles, then nucleic acid drugs can be encapsulated and delivered, but cytotoxicity increases and delivery efficiency decreases
Solution Approach 1:
The patent modifies the chemical structure of cationic lipids by changing parameters such as chain length, branching, and functional groups. Specifically, the invention uses lipids with optimized hydrophobic chain lengths (C16-C24) and specific headgroup structures (e.g., N,N-dialkyl-N-methyl amino groups) to reduce cytotoxicity while maintaining nucleic acid binding capability and delivery efficiency.
Solution Approach 2:
The patent employs composite lipid formulations combining multiple lipid types in specific ratios. The lipid composition includes ionizable cationic lipids (20-70 mol%), neutral lipids (10-40 mol%), cholesterol (10-30 mol%), and PEGylated lipids (0.5-10 mol%). This composite approach balances encapsulation efficiency, stability, and reduced cytotoxicity through synergistic effects of different lipid components.
2Quantity of substance
If cationic lipids are selected to improve entrapment efficiency of nucleic acid drugs, then delivery capability increases, but stability and safety decrease
Solution Approach 1:
The patent optimizes the ionization pKa of cationic lipids to between 6.0-8.0 through specific structural modifications. This parameter change allows the lipids to remain protonated and positively charged at acidic endosomal pH for effective nucleic acid entrapment, while being less aggressive at physiological pH, thereby improving both entrapment efficiency and formulation stability.
3Reliability
If novel lipid structures are developed to improve delivery efficiency, then in-vivo performance increases, but manufacturing complexity increases
Solution Approach 1:
The patent divides the lipid molecule into distinct functional segments: a hydrophobic tail region (C16-C24 chains), a linker region (ethylene glycol or alkyl chains), and a hydrophilic headgroup (ionizable amino groups). This segmentation allows independent optimization of each region's properties while maintaining overall molecular simplicity and ease of synthesis through modular chemical approaches.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The novel lipid compound enhances the in-vivo delivery efficiency of nucleic acid drugs by achieving high entrapment efficiencies and pH-responsive properties, ensuring effective and safe delivery to target organs.
Implementation Method 1
Development of a novel cationic lipid compound with a specific structure that can form a lipid carrier, allowing for controlled, uniform distribution and high entrapment efficiency of nucleic acid drugs
Implementation Method 2
exhibiting pH-responsive electric properties to minimize cytotoxicity
Data Source
AI summary
The present invention belongs to the technical field of gene therapy, and particularly relates to a series of lipid compounds as well as a lipid carrier, nucleic acid lipid nanoparticle composition and pharmaceutical preparation containing the same. A compound having a structure of a formula (I) provided by the present invention can be used for preparing a lipid carrier together with other lipid compounds, and exhibits pH response, and the entrapment efficiency to a nucleic acid drug is high, which greatly improves in-vivo delivery efficiency of the nucleic acid drug; and furthermore, a lipid compound with a specific structure can be chosen as a lipid carrier based on an organ in which the nucleic acid drug needs to be enriched, having a good market application prospect.